Gene and Cell Therapy – Products
Product
Advertisement
Comprehensive CAR-T Therapy Solutions
With six CAR-T drugs currently approved by the FDA and more to follow, Sino Biological has committed to developing reagents and services to support our clients in CAR development, CAR-T preparation and lentivirus packaging, CAR-T cell expansion, and CAR-T quality control.
Product News
Polyplus Launches FectoVIR®-LV Transfection Reagent with New DOE Service Options
Polyplus (now part of Satorius), is announcing the pre-order availability of FectoVIR®-LV transfection reagent for lentiviral vector (LV) production.
Product News
NIH and Exothera Collaborate To Produce GMP Intranasal Vaccine Against SARS-CoV-2
The National Institutes of Health selected Exothera S.A. therapeutics to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2.
App Note / Case Study
Data Reproducibility for the Development of Safer Gene Therapies
Immunogenicity is a key consideration in the development of safe gene therapy products. In fact, certain product components can cause unintended immune responses with life-threatening implications if not addressed.
Whitepaper
Combat Disruption in Gene Therapy Development
This whitepaper highlights common challenges in gene therapy development and explores the latest analytical approaches available to combat workflow disruption.
Product
Advertisement
GMP-Grade Cytokines for Cell Therapy Research
Sino Biological performs extensive quality control tests to ensure that GMP-grade cytokines meet rigorous quality standards, offering a range of GMP-grade cytokines
Product
Advertisement
View High-quality Cytokines Brochure
Sino Biological has launched a comprehensive collection of high-quality bioreagents to support the study and application of cytokines.
Compendium
Overcoming Lentiviral Development Challenges
This content pack contains a variety of webinars, technical notes and a compendium of resources to help you overcome a variety of common lentiviral development challenges. Download this content pack to discover innovative solutions for more comprehensive proteome characterization.
Product News
Cytiva Launches System To Enable End-to-End Manufacturing of Lipid Nanoparticle Medicines
Cytiva has launched the NanoAssemblr commercial formulation system, purpose-built for clinical and commercial manufacturing of lipid nanoparticle medicines.
Product News
Scribe Therapeutics Expands Collaboration With Sanofi To Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, announced an expanded collaboration with Sanofi.
Advertisement